Miglustat
- Atc Codes:A16AX06
- CAS Codes:72599-27-0
- PHARMGKB ID:72599-27-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Zavesca; Belgium: Zavesca; Bulgaria: Zavesca; Cyprus: Zavesca; Czech Republic: Zavesca; Denmark: Zavesca; Estonia: Zavesca; Finland: Zavesca; France: Zavesca; Germany: Zavesca; Greece: Zavesca; Hungary: Zavesca; Ireland: Zavesca; Italy: Zavesca; Latvia: Zavesca; Lithuania: Zavesca; Luxembourg: Zavesca; Malta: Zavesca; Netherlands: Zavesca; Poland: Zavesca; Portugal: Zavesca; Romania: Zavesca; Slovakia: Zavesca; Slovenia: Zavesca; Spain: Zavesca; Sweden: Zavesca; UK: Zavesca.
North America
Canada: Zavesca; USA: Zavesca.
Drug combinations
Chemistry
Miglustat: C~10~H~21~NO~4~. Mw: 219.28. (1) 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3R,4R,5S)-; (2)(2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)piperidine-3,4,5-triol. CAS-72599-27-0 (2003).
Pharmacologic Category
Other Miscellaneous Therapeutic Agents; Enzyme Inhibitor. (ATC-Code: A16AX06).
Mechanism of action
Miglustat competitively and reversibly inhibits enzyme needed to produce glycosphingolipids and decreases rate of glycosphingolipid glucosylceramide formation.
Therapeutic use
Treatment of mild-to-moderate type 1 Gaucher’s disease when enzyme replacement therapy not a therapeutic option.
Pregnancy and lactiation implications
Decreased fetus weight, fetal loss, and difficult or delayed births observed in animal studies. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to miglustat or any component of the formulation. Pregnancy.
Warnings and precautions
Diarrhea common. Peripheral neuropathy reported. Exacerbations of existing tremor or tremor might occur. Use with caution in renal impairment. Not recommended in severe impairment. Miglustat increases clearance of imiglucerase.